Terms: = Thyroid cancer AND PDGFRB, JTK12, 5159, P09619, ENSG00000113721, PDGF-R-beta, PDGFR1, CD140B, PDGFR, CD140b
51 results:
1. The Tyrosine Kinase Inhibitor Lenvatinib Inhibits Anaplastic thyroid Carcinoma Growth by Targeting Pericytes in the Tumor Microenvironment.
Iesato A; Li S; Sadow PM; Abbasian M; Nazarian A; Lawler J; Nucera C
Thyroid; 2023 Jul; 33(7):835-848. PubMed ID: 37171127
[No Abstract] [Full Text] [Related]
2. cancer-associated fibroblasts in papillary thyroid carcinoma.
Zhu L; Zhang X; Zhang S; Zhang Q; Cao L; Zhang Y; Wang D; Liang X; Wu W; Wu S; Jiang R; Liu Y; Zhao X; Zhou G; Xu K; Meng Z
Clin Exp Med; 2023 Oct; 23(6):2209-2220. PubMed ID: 36715834
[TBL] [Abstract] [Full Text] [Related]
3. Adrenal Cortical Carcinoma and Additional Rare Pathologic Findings in Multi-Organs in a Birt-Hogg-Dubé Syndrome Patient: With an Emphasis on the Molecular Characteristics of Adrenal Cortical Carcinoma.
Kim D; Murvelashvili N; Hamidi O; Jia L
Int J Surg Pathol; 2023 Aug; 31(5):689-694. PubMed ID: 35946080
[TBL] [Abstract] [Full Text] [Related]
4. The diagnostic performance of dynamic contrast-enhanced MRI and its correlation with subtypes of breast cancer.
Li X; Fu P; Jiang M; Zhang J; Tan L; Ai T; Li X
Medicine (Baltimore); 2021 Dec; 100(51):e28109. PubMed ID: 34941052
[TBL] [Abstract] [Full Text] [Related]
5. Tumor Microenvironment-Associated Pericyte Populations May Impact Therapeutic Response in thyroid cancer.
Iesato A; Nucera C
Adv Exp Med Biol; 2021; 1329():253-269. PubMed ID: 34664244
[TBL] [Abstract] [Full Text] [Related]
6. Donafenib: First Approval.
Keam SJ; Duggan S
Drugs; 2021 Nov; 81(16):1915-1920. PubMed ID: 34591285
[TBL] [Abstract] [Full Text] [Related]
7. Lenvatinib Targets pdgfr-β Pericytes and Inhibits Synergy With thyroid Carcinoma Cells: Novel Translational Insights.
Iesato A; Li S; Roti G; Hacker MR; Fischer AH; Nucera C
J Clin Endocrinol Metab; 2021 Nov; 106(12):3569-3590. PubMed ID: 34302727
[TBL] [Abstract] [Full Text] [Related]
8. The role of anlotinib-mediated EGFR blockade in a positive feedback loop of CXCL11-EGF-EGFR signalling in anaplastic thyroid cancer angiogenesis.
Liang J; Jin Z; Kuang J; Feng H; Zhao Q; Yang Z; Zhan L; Shen B; Yan J; Cai W; Cheng X; Qiu W
Br J Cancer; 2021 Aug; 125(3):390-401. PubMed ID: 34088989
[TBL] [Abstract] [Full Text] [Related]
9. pdgfr-β
Hu G; Huang L; Zhong K; Meng L; Xu F; Wang S; Zhang T
Aging (Albany NY); 2021 May; 13(10):13693-13707. PubMed ID: 33946048
[TBL] [Abstract] [Full Text] [Related]
10. Anlotinib in Locally Advanced or Metastatic Medullary thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial.
Li D; Chi Y; Chen X; Ge M; Zhang Y; Guo Z; Wang J; Chen J; Zhang J; Cheng Y; Li Z; Liu H; Qin J; Zhu J; Cheng R; Xu Z; Zheng X; Tang P; Gao M
Clin Cancer Res; 2021 Jul; 27(13):3567-3575. PubMed ID: 33832949
[TBL] [Abstract] [Full Text] [Related]
11. Anaplastic thyroid Carcinoma: Current Issues in Genomics and Therapeutics.
Abe I; Lam AK
Curr Oncol Rep; 2021 Feb; 23(3):31. PubMed ID: 33582932
[TBL] [Abstract] [Full Text] [Related]
12. Tyrosine kinase inhibitor therapy and metabolic remodelling in papillary thyroid cancer.
Wagner M; Wuest M; Lopez-Campistrous A; Glubrecht D; Dufour J; Jans HS; Wuest F; McMullen TPW
Endocr Relat Cancer; 2020 Sep; 27(9):495-507. PubMed ID: 32590338
[TBL] [Abstract] [Full Text] [Related]
13. Regulation of docetaxel chemosensitivity by NR2F6 in breast cancer.
Zhang J; Meng H; Zhang M; Zhang C; Huang M; Yan C; Wang Z; Hou L; Yang L; Ling R
Endocr Relat Cancer; 2020 May; 27(5):309-323. PubMed ID: 32203934
[TBL] [Abstract] [Full Text] [Related]
14. JAK/STAT3 and NF-κB Signaling Pathways Regulate cancer Stem-Cell Properties in Anaplastic thyroid cancer Cells.
Shiraiwa K; Matsuse M; Nakazawa Y; Ogi T; Suzuki K; Saenko V; Xu S; Umezawa K; Yamashita S; Tsukamoto K; Mitsutake N
Thyroid; 2019 May; 29(5):674-682. PubMed ID: 30784360
[No Abstract] [Full Text] [Related]
15. Whole-genome and transcriptome profiling of a metastatic thyroid-like follicular renal cell carcinoma.
Ko JJ; Grewal JK; Ng T; Lavoie JM; Thibodeau ML; Shen Y; Mungall AJ; Taylor G; Schrader KA; Jones SJM; Kollmannsberger C; Laskin J; Marra MA
Cold Spring Harb Mol Case Stud; 2018 Dec; 4(6):. PubMed ID: 30446580
[TBL] [Abstract] [Full Text] [Related]
16. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development.
Shen G; Zheng F; Ren D; Du F; Dong Q; Wang Z; Zhao F; Ahmad R; Zhao J
J Hematol Oncol; 2018 Sep; 11(1):120. PubMed ID: 30231931
[TBL] [Abstract] [Full Text] [Related]
17. Regorafenib.
Ettrich TJ; Seufferlein T
Recent Results Cancer Res; 2018; 211():45-56. PubMed ID: 30069758
[TBL] [Abstract] [Full Text] [Related]
18. Lenvatinib in the Therapy of Aggressive thyroid cancer: State of the Art and New Perspectives with Patents Recently Applied.
Ferrari SM; Ruffilli I; Centanni M; Virili C; Materazzi G; Alexopoulou M; Miccoli M; Antonelli A; Fallahi P
Recent Pat Anticancer Drug Discov; 2018; 13(2):201-208. PubMed ID: 29468981
[TBL] [Abstract] [Full Text] [Related]
19. Autocrine activation of platelet-derived growth factor receptor α in metastatic papillary thyroid cancer.
Adewuyi EE; Deschenes J; Lopez-Campistrous A; Kattar MM; Ghosh S; McMullen TPW
Hum Pathol; 2018 May; 75():146-153. PubMed ID: 29408504
[TBL] [Abstract] [Full Text] [Related]
20. [Lenvatinib in radioiodine refractory thyroid carcinomas].
de la Fouchardiere C
Bull Cancer; 2016 Nov; 103(11):905-910. PubMed ID: 27817859
[TBL] [Abstract] [Full Text] [Related]
[Next]
